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X-APL: An Improved Family-Based Test of Association
in the Presence of Linkage for the X Chromosome
Ren-Hua Chung, Richard W. Morris, Li Zhang, Yi-Ju Li, and Eden R. Martin
Family-based association methods have been developed primarily for autosomal markers. The X-linked sibling trans-
mission/disequilibrium test (XS-TDT) and the reconstruction-combined TDT for X-chromosome markers (XRC-TDT) are
the first association-based methods for testing markers on the X chromosome in family data sets. These are valid tests
of association in family triads or discordant sib pairs but are not theoretically valid in multiplex families when linkage
is present. Recently, XPDT and XMCPDT, modified versions of the pedigree disequilibrium test (PDT), were proposed.
Like the PDT, XPDT compares genotype transmissions from parents to affected offspring or genotypes of discordant
siblings; however, the XPDT can have low power if there are many missing parental genotypes. XMCPDT uses a Monte
Carlo sampling approach to infer missing parental genotypes on the basis of true or estimated population allele fre-
quencies. Although the XMCPDT was shown to be more powerful than the XPDT, variability in the statistic due to the
use of an estimate of allele frequency is not properly accounted for. Here, we present a novel family-based test of
association, X-APL, a modification of the test for association in the presence of linkage (APL) test. Like the APL, X-APL
can use singleton or multiplex families and properly infers missing parental genotypes in linkage regions by considering
identity-by-descent parameters for affected siblings. Sampling variability of parameter estimates is accounted for through
a bootstrap procedure. X-APL can test individual marker loci or X-chromosome haplotypes. To allow for different pen-
etrances in males and females, separate sex-specific tests are provided. Using simulated data, we demonstrated validity
and showed that the X-APL is more powerful than alternative tests. To show its utility and to discuss interpretation in
real-data analysis, we also applied the X-APL to candidate-gene data in a sample of families with Parkinson disease.
From the Bioinformatics Research Center, North Carolina State University, Raleigh (R.-H.C.; L.Z.); and Center for Human Genetics (R.-H.C.; L.Z.; Y.-
J.L.; E.R.M.) and Department of Anesthesiology (R.W.M.), Duke University Medical Center, Durham, NC
Received August 31, 2006; accepted for publication October 25, 2006; electronically published November 28, 2006.
Address for correspondence and reprints: Dr. Eden R. Martin, Duke University Medical Center, Box 3468, Durham, NC 27710. E-mail: emartin
@chg.duhs.duke.edu
Am. J. Hum. Genet. 2007;80:59–68.  2006 by The American Society of Human Genetics. All rights reserved. 0002-9297/2007/8001-0007$15.00
Family-based association methods are often used for lo-
calizing genes in complex diseases when family data are
available; however, methodological developments have
focused primarily on analysis of autosomal markers.1–5
Linkage analyses have identified regions on the X chro-
mosome for several diseases, such as Parkinson disease (PD
[MIM 168600]),6,7 autism (MIM 209850),8,9 and early-onset
cardiovascular disease.10 Although association analysis is
often applied to further localize disease-susceptibility
genes in linkage regions, fine mapping of such regions on
the X chromosome has been slow, in part because of the
lack of appropriate statistical methods for family-based
association analysis on the X chromosome.
The X-linked sibling transmission/disequilibrium test
(XS-TDT) and the reconstruction-combined TDT for X-
chromosome markers (XRC-TDT), proposed by Horvath
et al.,11 are the first family-based association methods that
test X-chromosome markers specifically. These are valid
tests of association in family designs that include a single
proband, such as triads or discordant sib pairs. For families
with multiple affected offspring, these tests, which assume
independent gamete transmissions from parents to af-
fected siblings, can have an inflated type I error rate when
linkage is present between a marker and the disease locus.
This is the same problem faced by the original TDT and
sibling TDT (S-TDT).2 Because association analyses are of-
ten conducted in regions showing evidence of linkage, it
is critical that family-based association tests allow for the
presence of linkage under a null hypothesis of no asso-
ciation when multiple affected offspring are available.
More recently, the pedigree disequilibrium test (PDT),
originally proposed for autosomal markers by Martin et
al.,2,3 was extended to markers on the X chromosome.12 This
approach, the XPDT, maintains the properties of the PDT—
namely, it is a test of association in the presence of linkage
(APL) in general pedigrees, is valid in stratified populations,
and does not require specification of model parameters.
However, in families with missing parental data, the XPDT
uses only same-sex discordant sibships and, thus, may not
have optimal power. Recognizing this possibility, Ding et
al.12 suggested a Monte Carlo approach for inferring missing
parental data, the XMCPDT. They show that this approach
generally has more power than the XPDT, and the power
difference increases with an increasing amount of missing
parental data. A limitation of the XMCPDT is that allele
frequencies must be provided. Unknown allele frequencies
are estimated from known parental (founder) genotypes,
but the statistic does not account for variability in this es-
timate. Although the examples simulated by Ding et al.12
show no inflation of type I error, the validity of the test
with varying amounts of missing parental data has not been
thoroughly examined.
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Here, we extend the APL method,13 developed for au-
tosomal markers, to the analysis of X-chromosome mark-
ers in nuclear families. Like the APL, our proposed pro-
cedure, which we refer to as “X-APL,” properly infers
missing parental genotypes in regions of linkage by con-
sidering identity-by-descent (IBD) parameters for affected
siblings. We use a bootstrap procedure to adjust for the
variation in parameter estimates, which does not assume
that allele frequencies are given. X-APL can perform both
single-locus and haplotype association tests. Recognizing
the existence of sex-limited traits, we introduce into the
X-APL separate tests for males and females that allow in-
ference about different effects in the sexes.
We used computer simulations to demonstrate the va-
lidity of the X-APL statistic and to examine robustness and
power. We compared the power of the X-APL with the
power of the XS-TDT, XPDT, and XMCPDT, under a range
of models and sampling schemes. We compared the power
of the X-APL test using all data with that of separate tests
for males and females under sex-specific penetrance mod-
els. We then applied X-APL to a real data set containing
families with PD. We tested markers in two X-linked genes,
monoamine oxidase A and B (MAOA [MIM 309850] and
MAOB [MIM 309860]), which have been examined else-
where as candidate genes for PD.14–18
Methods
The X-APL statistic is a modification of the APL statistic.13 The
APL statistic is based on the difference between the observed
number of copies of a specific allele in affected siblings and the
expected number of copies conditional on parental genotypes,
under the null hypothesis that there is no association or no link-
age in nuclear families. When parental genotypes are missing,
APL infers missing parental genotypes by using siblings’ geno-
types and accounts for linkage by taking the IBD parameters into
consideration (see the work of Martin et al.13 for details). The APL
software can analyze families with up to three affected siblings
and arbitrary numbers of unaffected siblings.19
X-APL Statistic
The X-APL is designed for nuclear families with one or more
affected siblings. First, consider a sample of n families, each with
two affected siblings. Markers are assumed to be biallelic, with
alleles 1 and 2 on the X chromosome. We denote Ij as the number
of copies of allele 1 in the affected siblings in the jth family. In
the work of Martin et al.,13 the APL statistic Tj is the difference
between Ij and the conditional expected value of , whereI , E(I FG )j j pj
the parental genotypes are represented by in the jth family.Gpj
To extend the APL statistic to X-chromosome markers, we con-
sider the sexes of the siblings when calculating the expected value
of Ij. We define m as an affected male sibling, f as an affected
female sibling, and “sex” as the combination of sexes of the af-
fected siblings, which is (m,m) if both affected siblings are male,
(m,f) if one affected sibling is male and the other is female, and
(f,f) if both affected siblings are female.
Under the null hypothesis, the expected value of Ij can be es-
timated conditionally on the parental genotypes and sexes of the
affected siblings:
N if sexp (m,m)fj
E(I FG ,sex)p N N if sexp (m,f) ,j pj fj mj{ }
N  2N if sexp (f,f)fj mj
where Nfj, the number of allele 1 in the female parent, takes value
0, 1, or 2 and Nmj, the number of allele 1 in the male parent, takes
value 0 or 1 in the jth family. The expected value of Ij for a
singleton family has a simpler form. isE(I FG ,sexp m) (1/2)#j pj
, and is . We define the statisticN E(I FG ,sexp f) (1/2)#N Nfj j pj fj mj
Tj to be in the jth family. In complete ped-T p I  E(I FG ,sex)j j j pj
igrees, Nfj and Nmj can be counted directly from the parental data,
and the transmissions from male parent to affected siblings cancel
in Tj; therefore, male parents provide no information for the X-
APL statistic in complete pedigrees.
Although calculation of the statistic Tj is straightforward if the
parental genotypes are available, parental genotypes are often
missing for individuals with late-onset diseases. In that case, we
must infer missing parental genotypes on the basis of the siblings’
genotypes. In equation (2) in the work of Martin et al.,13 the
probability of a parental mating type, , was estimatedPr (G FG,A)p
on the basis of siblings’ genotypes G and their affection status
A. We modified this probability for X-APL by also conditioning
on the sexes of the siblings. Like the APL for autosomes, the IBD
parameters for an affected sibling pair are used to account for
linkage between a marker and a disease locus when the missing
parental genotypes are being inferred. The IBD for the alleles
transmitted from the male parent is fully determined by the sexes
of the affected sibling pair. That is, when we consider IBD sharing
for alleles transmitted from the male parent, the affected siblings
share 0 alleles IBD when or (m,f) and 1 allele IBDsexp (m,m)
when . Thus, only IBD status for alleles transmittedsexp (f,f)
from the female parent needs to be estimated. The affected sib-
lings share either 0 or 1 alleles IBD from the female parent.
When there is tight linkage and no association, the probability
is similar to equation (2) in the work of MartinPr (G FG,A,sex)p
et al.13 and can be written as
1
m  z Pr (GFG ,IBDp k,sex)G k pp
kp0Pr (G FG,A,sex)p ,p Pr (GFA,sex)
where is the unconditional probability of parental mating typemGp
Gp and zk is the probability that the affected siblings share k alleles
IBD from the female parent. Since disease penetrances are ex-
pected to be low for any particular locus for complex diseases,
transmissions to the unaffected siblings are assumed to be in-
dependent of disease status. Then, IBD parameters for an unaf-
fected sibling pair, or for a pair with one affected and one un-
affected sibling, can be approximated by .(z ,z )p (1/2,1/2)0 1
Therefore, when there are unaffected siblings in a family, the
probabilities are multiplied by the Men-Pr (GFG ,IBDp k,sex)p
delian transmission probabilities for the unaffected siblings for
given parental genotypes. The expectation-maximization (EM)
algorithm is used to estimate the parameters and zk. The pro-mGp
cedures of the EM algorithm for estimating the mating-type and
IBD parameters are similar to those used by Martin et al.13 For
singleton families, the probability reducesPr (GFG ,IBDp k,sex)p
to , which depends only on Mendelian transmissionPr (GFG ,sex)p
probabilities. When parental genotypes are missing, the expec-
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tation of Ij is given by the expectation of with respectE(I FG ,sex)j pj
to the conditional distribution of parental genotypes, as follows:
T p I  Pr (G FG ,A,sex)E(I FG ,sex) ,j j pi j i pi
iQ
where Q is a set of all possible parental mating types. Partial pa-
rental genotypes can be used to improve estimation of the pa-
rental mating-type parameters, with use of the same methods
discussed in the work of Martin et al.13 Let Ts be the sum of Tj
over families; then, under the null hypothesis that there is no
association or no linkage, the expected value of the statistic Ts is
0. The X-APL test is based on this summary statistic, Ts.
Variance Estimation
Martin et al.13 used a robust estimator to estimate the variance
of the APL statistic. However, the estimator is difficult to imple-
ment in practice when various nuclear family structures exist in
a data set. In the work of Chung et al.,19 a bootstrap variance
estimator, which offers more flexibility for analysis of different
family structures, was proposed to replace the original variance
estimator. The bootstrap approach can be applied to the X-APL
model as well. Families are resampled with replacement to form
each bootstrap replicate, and a new Ts is calculated for each rep-
licate. If B bootstrap replicates are performed, then the sample
variance can be obtained from the B values of Ts. WhenˆVar(T )s
B is large, the sample variance will be asymptotically close to the
variance of Ts.
Finally, the X-APL statistic takes the form
Ts .
ˆVar(T )s
Under the null hypothesis of no linkage or no association, this
statistic is asymptotically normal, with a mean of 0 and a variance
of 1.
Separate Tests for Males and Females
Disease loci can have different effects on males and females. Al-
though a test using combined data could still find association
between disease and markers, separate tests for males and females
may be more powerful and informative for sex-specific effects. A
straightforward approach to test association for males and females
separately is to divide the transmissions from parents to affected
siblings into separate transmissions to affected male and female
siblings. They can be calculated using the parental mating-type
and IBD parameters estimated by all data from both sexes. How-
ever, when a marker is in linkage disequilibrium (LD) with a dis-
ease locus, estimating parameters with the use of all data may
not be appropriate for separate tests, particularly when the disease
locus has an effect in only one sex. The parameters may not be
estimated properly, since they are estimated under the null hy-
pothesis that the marker alleles are not associated with the disease
in either sex. Our simulation results showed that type I errors for
the X-APL statistic for the sex with no disease-locus effect can be
inflated when all data are used to estimate the parameters. A
solution is to divide the data into two sets: one set that has only
male affected siblings and another set that has only female af-
fected siblings. The two sets may have overlapping families if
some families have both affected male and female siblings. All
unaffected individuals are retained in both sets. Then X-APL tests
can be applied separately on the two sets with use of parameters
estimated in their respective sets. We refer to the test using only
male affected sibs and the test using only female affected sibs as
“X-APL male” and “X-APL female,” respectively. Since both male
and female tests can be performed simultaneously, multiple test-
ing should be considered when we interpret the P values from
the two tests. An adjustment for the P values, such as Bonferroni
correction, may be required to interpret the P values properly.
Extension to Multiple-Marker Haplotype Analysis
To extend the X-APL test to a multiple-marker haplotype test, we
assume that no recombination occurs between the markers
within the families in the sample. The strategy of haplotype test-
ing is analogous to a multiple-allele analysis for a single marker,
but with haplotype phase not always known. Probabilities of con-
sistent haplotype phases within each family are estimated jointly
with the estimation of IBD parameters and haplotype frequencies,
with the use of the EM algorithm. Only phase probabilities for
females need to be estimated, since phase for the non-missing
male is always known. A global test statistic, G, which follows an
asymptotic x2 distribution under the null hypothesis that none
of the haplotypes is associated with the disease locus, is calculated
using the method described by Chung et al.19 to measure the
overall haplotype effect, , where the vector Ts con-′ 1Gp T S Ts s
tains the X-APL statistics for each possible haplotype and is theS
variance-covariance matrix of Ts. If h is the number of haplotypes
tested, then the statistic G is asymptotically distributed as x2 with
df.h 1
A global test for all haplotypes can be more informative than
individual haplotype tests, since it can capture multiple haplo-
type effects.20 The global test also can have more power than
individual haplotype tests because it does not have the multiple-
testing issue faced when analyzing haplotypes individually.21
Moreover, in the X-APL test, IBD and parental mating-type pa-
rameters are estimated under the global null hypothesis that none
of the haplotypes are in LD with a disease allele. It is not straight-
forward to estimate those parameters under a haplotype-specific
null hypothesis. For these reasons, we base inference solely on
the global test for haplotype analysis.
Hardy-Weinberg Equilibrium Assumption
Hardy-Weinberg equilibrium (HWE) for haplotype frequencies is
assumed in X-APL for the haplotype test, to reduce the number
of parameters estimated by the EM algorithm. The same as-
sumption is also applied to the separate male and female tests.
For single-marker analyses, we implement two versions of X-APL,
one with and one without an HWE assumption. In real data anal-
ysis, genotyping errors, mutations, and population stratification
may cause genotype frequencies to deviate from HWE. We used
computer simulations to generate data sets with different degrees
of deviation from HWE, by combining samples from two random-
mating populations with different allele frequencies into one data
set. To evaluate deviation from random mating, we generated
data with two markers to evaluate the effect for haplotype tests.
The HWE goodness-of-fit (GOF) test statistic, which has an as-
ymptotic x2 distribution, was used to measure the degree of HWE
deviation. Note that we can measure this deviation only in fe-
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RecA .25 5.00 .0063
RecB .25 4.00 .0059
RecC .25 3.00 .0056
RecD .25 2.50 .0054
RecE .25 2.00 .0053
RecF .25 1.50 .0052
Multiplicative:
MultA .15 7.50 .0064
MultB .15 6.25 .0060
MultC .15 4.00 .0053
MultD .15 3.06 .0049
MultE .15 2.25 .0046
MultF .15 1.56 .0043
Null .25 1.00 .0023
a GRR for female p fDD/fdd. GRR for male p fD/fd.
f is the penetrance function for disease allele D.
males, since males are haploid for the X chromosome. The HWE
GOF statistic was calculated as
2[nP(h h ) nP(h )P(h )]i j i j ,
nP(h )P(h )i,jW i j
where n is the number of female parents and P( ) and P( ) areh hi j
the estimated allele frequencies from the mixed population for
alleles hi and hj, respectively. For single-marker analyses, P(hihj) is
the estimated genotype frequency in the mixed population, and
w is a set of all alleles for the marker. For haplotypes with two
markers, P(hihj) is the estimated haplotype frequency, and w is a
set of all haplotypes between the two markers. Hence, the de-
viations from HWE in the data set were simulated with respect
to haplotype frequencies for the two markers. We investigated
the effects of deviations of allele or haplotype frequencies from
HWE expectations with the X-APL test using all data and with
the separate male and female tests.
Computer Simulations
Computer simulations were used to evaluate the type I error and
power of X-APL. We used the SIMLA computer program22 to gen-
erate samples of families on the basis of different disease models.
Family ascertainment included the following family structures:
one affected offspring with one unaffected sibling (AU), one af-
fected sibling pair (AA), and one affected sibling pair plus one
unaffected sibling (AAU). No parental genotypes were available
in these families, except as noted in the tables.
The SIMLA parameters used in our simulations are shown in
table 1, which contains six recessive models (RecA, RecB, RecC,
RecD, RecE, and RecF) and six multiplicative models (MultA,
MultB, MultC, MultD, MultE, and MultF) with different preva-
lences and genotypic relative risks (GRRs).13 The null model,
shown in table 1 with , was used to simulate disease lociGRRp 1
that have no effect on a specific sex. The GRR for females is the
penetrance function for homozygous disease alleles (fDD) divided
by the penetrance function for homozygous normal alleles (fdd).
The GRR for males, assumed to be hemizygous, is the penetrance
of the disease allele (fD) divided by the penetrance of the normal
allele (fd). Hence, when for each sex, the disease loci doGRRp 1
not contribute to the disease phenotype. When , the dis-GRR 1 1
ease alleles increase the risk of developing the disease phenotype.
By default, we simulated samples in which males and females
have the same prevalence and GRR; for example, GRR for females,
fDD/fdd, is equal to GRR for males, fD/fd. The sex ratio of males to
females is 1:1 because of the equal disease prevalence. Samples
with different GRRs and prevalences for males and females were
also generated to reflect disease loci with different effects in the
different sexes. In cases of unequal prevalences in males and fe-
males, the sex ratio is determined by the prevalence in males to
the prevalence in females.
For type I error simulations, we assumed that disease and
marker loci were tightly linked (there was no recombination be-
tween them), but there was no association between the disease
and marker alleles, except as noted below (scenario 4). Four sce-
narios were simulated (scenarios 1, 2, 3, and 4), each with dif-
ferent family structures and disease models as described in table
2. In scenario 4, the marker and disease locus were in strong LD,
but the GRR was 1 for one sex and 11 for the other. To evaluate
type I error for multiple-marker haplotype tests, three markers
were simulated with eight possible haplotypes. The haplotype
frequencies were 0.512, 0.128, 0.128, 0.032, 0.128, 0.032, 0.032,
and 0.008 for haplotypes 111, 112, 121, 122, 211, 212, 221, and
222, respectively. As indicated by Chung et al.,19 rare haplotypes
may affect the validity of the global haplotype APL statistic. Rare
haplotypes may also affect the X-APL statistic, particularly when
samples are stratified into male and female tests. Hence, we in-
creased the number of families to 1,000 in scenarios 1, 3, and 4
for haplotype analyses.
Power simulations assumed that the marker and disease alleles
were in perfect LD for single-locus tests, so that the marker locus
was, in fact, equivalent to the disease locus. The AU, AA, and
AAU family structures with all parents missing were simulated.
For multiple-marker haplotype tests, two markers were simulated
as having four possible haplotypes—11, 12, 21, and 22—with
frequencies 0.3, 0.3, 0.2, and 0.2, respectively. Haplotype 11 was
set to be the risk haplotype and was the only haplotype positively
associated with the disease allele.
To compare the power between the X-APL test using all data
and the separate male and female tests, we simulated two addi-
tional scenarios (scenarios 5 and 6) as described in table 2. The
two scenarios were simulated, with 250 AAU families with all
parental genotypes missing, under the recessive model.
For comparison with X-APL, we used an SAS macro, which can
be downloaded from Michael Knapp’s Web site, to conduct the
XS-TDT and XRC-TDT.11 An R program provided by Ding et al.
was used to conduct the XPDT and XMCPDT (MC-PDT Web
site).12 Asymptotic P values provided by the software were used
to evaluate significance.
Results
Type I Error and Power
We first considered the effect of linkage on the XRC-TDT
and XS-TDT as tests for association using computer sim-
ulations. Table 3 shows estimates of type I error for disease
models RecA and MultA (from table 1) based on 5,000
replicate data sets with all parents missing. We found that,
when multiple affected siblings are present, both XS-TDT
and XRC-TDT have inflated type I error rates. For example,
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Table 2. Scenarios Simulated for Different Family Structures and Genetic Effects
Scenario Samplea Male:Female GRRb
For type I error:
1c 300 AAU (1,000 AAU) Equal
2 250 AAU  250 AAU* Equal
3c 300 AAU (1,000 AAU) Unequal
4c 300 AAU (1,000 AAU) Sex-limited ( in one sex)GRRp 1
For power:
5 250 AAU Equal
6 250 AAU Sex-limited ( and lower disease prevalence in one sex)GRRp 1
a AAU families have two affected and one unaffected sibling with parental genotypes missing. AAU* families
are the same as AAU families but have genotype data available for one parent.
b GRRs and prevalences are determined on the basis of the disease models in table 1.
c For haplotype analyses, 1,000 AAU families were used.
Table 3. Type I Error of XRC-TDT and XS-TDT for







ap .05 ap .005 ap .05 ap .005
300:
RecA .060 .006 .070 .011
MultA .062 .006 .088 .016
600:
RecA .060 .006 .077 .011
MultA .060 .007 .078 .016
a Proportion of data sets with .P  a
with significance level .05, XS-TDT has a type I error rate
0.062, and XRC-TDT has a type I error rate 0.088 for the
300 AAU families simulated under the disease model MultA.
Unlike XS-TDT and XRC-TDT, the XPDT and XMCPDT al-
low for correlation among multiple affected siblings. In our
simulations, we found that the type I error of the XPDT
and the XMCPDT, with use of the true allele frequencies,
are close to the nominal level (type I error estimates range
from 0.045 to 0.054 at the nominal level of .05).
We examined the impact of varying the sample size and
the proportion of families with parental information on
the XMCPDT, using allele frequencies estimated from the
observed parental genotypes (table 4). When the propor-
tion of families with parental information is small, we
found that the type I error for XMCPDT can be inflated.
For example, when there are 50 AAU families with paren-
tal information and 300 AAU families with no parental
information, XMCPDT has a type I error rate 0.077 with
a nominal significance level .05. This inflation of type I
error was seen in both singleton and multiplex families.
When the proportion of families with parental informa-
tion increases, XMCPDT can have a reasonable type I error
rate, though an upward bias is still evident (table 4).
Table 5 shows estimates of type I error for X-APL for
single-marker and global haplotype tests. Type I error es-
timates for male and female tests are also shown. Under
different disease models and family structures, the type I
error rate is close to the nominal level of .05 for both
single-marker and global haplotype tests. In scenario 4,
where the marker and disease loci are in LD and the disease
locus has an effect only in males, the female tests show
correct type I error rates. In the reverse case—that disease
locus has an effect only in females—the type I error rates
for the male tests were also correct (data not shown). Type
I error rates for a nominal level of .005 were also estimated,
and they were also close to the nominal level (data not
shown).
Even though, as a test for association, XS-TDT does not
account for linkage when multiple affected siblings are
present, its type I error rate is not severely inflated for the
significance level ( and .005) in our simulationsap .05
(table 3). Hence, we compared the power of X-APL with
that of XS-TDT, as well as with that of XPDT, under dif-
ferent disease models and nuclear-family structures. Since
the type I error rate is reasonable for XMCPDT when the
proportion of families with parental information is large,
we included power comparisons with XMCPDT in such
cases. We considered two significance levels for power cal-
culations: .05 and .005. Figure 1 shows that the X-APL
outperforms XS-TDT, XPDT, and XMCPDT in the six dis-
ease models considered. We did not show the power for
RecA, RecB, RecC, MultA, MultB, and MultC models in
figure 1, since X-APL has a power of 1 for these models.
For the data sets that have 250 AAU families without pa-
rental information, X-APL typically has substantiallymore
power than XS-TDT and XPDT at significance level .005.
As mentioned by Martin et al.,13 even families with no
unaffected siblings and no parental information can add
some power to the APL. We also observed that adding AA
families to AAU families gives more information for the
X-APL, whereas XS-TDT and XPDT maintain the same
power because they do not use AA families (fig. 1). With
a total sample size of 250 AAU families, we also simulated
100 AAU families with parental information and 150 AAU
families with no parental information. Compared with the
power for 250 AAU families with no parental information,
the power for X-APL, XS-TDT, and XPDT is higher when
some parental information is available. In the case of
larger sample size (250 AAU with information for one par-
ent and 250 AAU with missing parental information), we
can see that all of the tests have increasing power. In ex-
amples with parental data, XMCPDT can have power com-
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Table 4. Type I Error of XMCPDT for
5,000 Simulated Data Sets
Family Structure
Type I Errora
ap .05 ap .005
50 AUb  300 AUc .077 .011
50 AAUb  300 AAUc .077 .011
100 AAUb  250 AAUc .058 .006
250 AAUd  250 AAUc .059 .008
a Proportion of data sets with .P  a
b Both parental genotypes are available.
c Genotypes are missing for both parents.
d Genotype is missing for one parent.
parable to that of X-APL. However, when the significance
level is reduced to .005, X-APL shows notably more power
than does XMCPDT. We also simulated 100 AU families
with parental information and 150 AU families with no
parental information, to evaluate the power for families
with only a single proband. The same pattern as in figure
1 was also observed—namely, that X-APL still shows more
power than do other tests (data not shown).
We also compared the power of the X-APL single-marker
test using all data with that of the X-APL male and female
tests for three cases—both sexes together and each sex
separately. We applied a Bonferroni correction to the P
values from male and female tests. We compared the
power for the X-APL test using all data at significance level
.05 with the power for male and female tests at signifi-
cance level .025. Table 6 shows that the X-APL test using
data for both sexes has more power than the separate tests
for each sex have when the disease locus has effects on
both males and females (scenario 5). However, when the
disease locus affects only one sex (scenario 6), separate
tests can be more powerful. From table 6, we can see (sce-
nario 6) that separate tests have similar or more power
than does the test using all data, even with the use of a
conservative multiple-testing correction. We can also see
that the type I error for the male or female test for the
sex not affected by the disease locus is close to the .025
nominal level, as expected.
From table 6, we see that the power for the separate test
in females is consistently lower than that for the separate
tests in males, even when the same GRRs are specified in
the two sexes. This is a consequence of the models selected
and the constraints on model parameters. For example,
in scenario 5, males and females have the same disease
prevalence and GRR. This forces the phenocopy rate under
a recessive model to be higher in females than in males,
which, as a consequence, reduces power for the female
test relative to the male test. Varying the relative disease
prevalence in males and females also influences power
because we have fixed the total sample size. For scenario
6, where the sex ratios are 7:3 and 3:7 and the genetic
effect is present in the sex with the higher disease prev-
alence, the sex-specific test has more power than in sce-
nario 5, where the sex ratio is 1:1.
HWE Effect
Table 7 shows type I error estimates for the single-marker
X-APL test for data containing deviations from HWE. The
version of the single-marker X-APL test that assumes HWE
for genotype frequencies was tested. For different degrees
of deviations from HWE, in table 7, type I error estimates
are all close to the .05 nominal level. Thus, even in ex-
treme cases where all parental information is missing and
there are severe deviations from HWE in the data, the
single-marker X-APL test is still valid at a significance level
of .05. Another version of the X-APL test that does not
assume HWE was also tested for the same data sets and
has correct type I error as well (data not shown). Our
power simulations showed that X-APL with the assump-
tion of HWE has more power than X-APL without the
HWE assumption, regardless of whether HWE really exists
(data not shown). Table 7 also shows estimates of the type
I error for the X-APL test for the global haplotype test.
The type I error is inflated when deviations from HWE are
present. More-severe departures from HWE cause more-
liberal global haplotype tests.
MAO Genes for PD
We applied X-APL, XS-TDT, and XPDT to the data set used
by Kang et al.18 A total of 774 families—558 singleton
families and 216 multiplex families—were used for the
overall X-APL test. Since 615 of these 774 families have
no parental information, XMCPDT was not included for
analysis. A total of 530 families—437 singleton families
and 93 multiplex families—were used for the male test. A
total of 329 families—288 singleton families and 41 mul-
tiplex families—were used for the female test. Table 8
shows the results for X-APL with all data and for separate
male and female tests, as well as the results obtained by
XS-TDT and XPDT. X-APL found that marker RS3027452,
located in intron 5 in MAOB, was significant ( )Pp .036
for the female test at significance level .05, whereas XS-
TDT and XPDT did not show significant results. However,
with a Bonferroni correction for multiple testing for the
male and female test, may not be considered aPp .036
significant result. We also applied the X-APL global hap-
lotype test to the markers in MAOA and MAOB but did
not observe a significant haplotype association with PD.
Discussion
We have developed the X-APL for testing association in
family-based designs for markers on the X chromosome.
Our simulation analyses show that X-APL has the correct
type I error rate. This is not generally true for XS-TDT and
XRC-TDT, which have inflated type I error when linkage
is present and there are multiple affected siblings in the
data. Inheriting the properties of PDT, XPDT does have
the correct type I error rate in the linkage region for fam-
ilies with multiple affected siblings. XMCPDT, which can
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Table 5. Type I Error of the X-APL Tests for 5,000 Simulated Data Sets
Scenario and Model of Inheritance
X-APL Type I Errora
Single Marker Global Haplotype
Allb Malec Femaled Allb Malec Femaled
1:
RecA .047 .052 .051 .056 .052 .051
RecB .050 .054 .055 .057 .055 .057
MultA .049 .049 .051 .049 .052 .056
MultB .047 .053 .047 .053 .051 .054
2:
RecA .046 .054 .044 .045 .051 .055
MultA .046 .052 .047 .048 .053 .051
3:
RecA in male, RecC in female .053 .045 .051 .048 .050 .055
MultA in male, MultC in female .048 .045 .049 .048 .045 .053
4e:
RecA … … .053 … … .048
MultA … … .053 … … .052
a Proportion of data sets with .P  .05
b X-APL test using all data.
c X-APL male test.
d X-APL female test.
e Disease locus affects males but not females; thus, type I errors occur only in females.
infer missing genotypes conditional on population allele
frequency, relies on the availability of at least some pa-
rental genotypes to estimate population allele frequency.
As demonstrated in our simulations, when the proportion
of genotyped parents is low, XMCPDT may not be a valid
test. It is also worth noting (table 3) that the type I error
rate of XS-TDT is not substantially inflated and is much
closer to the nominal level than is the type I error rate of
XMCPDT.
Our simulation results showed that X-APL is more pow-
erful than XS-TDT, XPDT, and XMCPDT for the six disease
models used for single-marker analyses in our simulations.
As mentioned by Horvath et al.,11 the partition of siblings
into same-sex groups can result in reduced power for XS-
TDT. XPDT also requires that the discordant sib pairs be
of the same sex.12 X-APL does not require this partitioning,
which contributes to its increased power. An unexpected
observation was that XS-TDT consistently has more power
than XPDT. This difference may be due to the hypergeo-
metric distribution assumed in XS-TDT, which better ap-
proximates the distribution of the test statistic under the
alternative hypothesis than the asymptotic distribution
used by XPDT.
Our simulation results show that the X-APL test using
data from both sexes can have more power than separate
X-APL male and female tests when the X-linked disease
locus contributes to disease risk for both sexes (scenario
5). On the other hand, when the X-linked disease locus
affects only one sex, separate tests can have more power
than the test using all data (scenario 6). However, some
information may be lost when the data are divided into
separate smaller data sets. Moreover, separate male and
female tests give rise to a multiple-testing issue, and a
correction may be required in assessing significance of the
tests. We found that, even if we used a conservative Bon-
ferroni correction for the P values from separate tests, the
separate tests still have somewhat more power than the
test using all data when disease loci affect only one sex.
Therefore, we suggest that, in practice, tests using all data
and separate male and female tests should be performed
to capture the most information in the data. The same
strategy for male and female tests can be applied to XPDT
as well. Our expectation—that it would have less power—
is, in fact, consistent with the previous real data analysis
for the MAOB gene.18
We are not aware of any haplotype test other than X-
APL for the X-chromosome markers. Consequently, we
estimated power for the global haplotype test of X-APL,
using computer simulation, and the results were reason-
able. X-APL fills the gap for family-based haplotype as-
sociation analysis on the X chromosome and will be very
useful for haplotype analyses in real data applications.
When compared with APL for autosomal markers, X-APL
shows considerably more power for the global haplotype
test using the same disease models and family structures
(data not shown). One reason that we expect to find more
power for haplotype analysis on the X chromosome com-
pared with autosomes is that the phases for male haplo-
types are determined explicitly for X-chromosome mark-
ers. Therefore, haplotype phases can be inferred more
precisely in X-APL than in APL. When data from both
parents are present, the haplotype phases can be exactly
determined. When data from both parents are missing in
a family, the haplotype of a male sibling determines one
haplotype in the female parent. Moreover, the male parent
is known to carry one Y chromosome, and the other hap-
lotype in the male parent can be determined by a female
sibling. Hence, there are fewer possible parental mating
Figure 1. Power comparison for single-marker analysis. Power estimates for the single-marker X-APL, XS-TDT, XPDT, and XMCPDT were
based on 2,000 simulated data sets. All families were simulated without parental data except AAU** families, which have both parents
present, and AAU* families, which have one parental genotype missing. Power is calculated for both significance levels (a) of .05 and
.005 for both the recessive and multiplicative models.
www.ajhg.org The American Journal of Human Genetics Volume 80 January 2007 67
Table 6. Power Estimates for X-APL Test Using All Data and for Separate Tests






ap .050 ap .025 ap .025
5:
RecD in both sexes 1:1 .944 .688 .140
6:
RecD in male, null model in female 7:3 .990 .997 .023c
Null model in male, RecD in female 3:7 .214 .023c .218
a Sex ratio for males to females in the affected siblings is calculated by the prevalence of
males to the prevalence of females in the population.
b Proportion of data sets with .P  a
c Estimates of type I error for the test, since disease loci have no effect in the sex.









RecA .052 .046 .043 .053
RecB .048 .053 .047 .050
MultA .047 .043 .046 .052
MultB .052 .047 .057 .051
2.479:
RecA .046 .048 .052 .073
RecB .049 .047 .049 .068
MultA .048 .046 .052 .075
MultB .054 .045 .050 .070
5.055:
RecA .053 .046 .050 .122
RecB .043 .043 .048 .115
MultA .043 .043 .052 .096
MultB .052 .044 .048 .100
NOTE.—300 AAU families without parental ge-
notypes were simulated with HWE deviations for
RecA, RecB, MultA, and MultB models.
a Larger value means larger deviation from HWE.
b Proportion of data sets with .P  .05
types that need to be considered compared with the au-
tosomal data, which can reduce the variance of estimates
of missing parental mating types. Although these obser-
vations are merely of academic interest, since a disease
locus is either on the X chromosome or is not, they suggest
that the X-APL haplotype test performance is consistent
with expectations.
We also examined the robustness of X-APL for data con-
taining deviations from HWE. Our simulation results showed
that the X-APL test for single-marker analysis is robust to
deviations from HWE in the data. Since the X-APL test with
HWE assumption has more power than the X-APL test with-
out HWE assumption for single-marker analysis, the version
of X-APL with HWE assumption will be preferred for most
real-data analyses. For global haplotype analyses, violations
of HWE for haplotype frequencies can significantly inflate
type I errors for X-APL. Therefore, haplotype analyses are
not reliable in data sets deviating from HWE.
The monoamine oxidase genes MAOA and MAOB are
located on the X chromosome and have been found to
be associated with PD.14–18 In Kang et al.,18 a total of 644
families with PD, consisting of both singleton and mul-
tiplex families, were used for association studies. The
PDT,2,3 developed for autosomal markers, was used by
Kang et al.,18 who divided the whole data set into female
and male siblings. The marker RS1799836, located in in-
tron 13 in MAOB, showed significant association with PD
in the data set containing only female siblings ( ).Pp .022
The X-APL female test showed significant association for
marker RS3027452, located in intron 5, but, again, the
effect was restricted to females. This suggests that the
MAOB gene might have an effect for PD in females but
not in males. Our results are not entirely consistent with
the results obtained by Kang et al.,18 since different mark-
ers show significance in the different analyses. The in-
consistency may be due to the fact that Kang et al.18 re-
stricted analysis to same-sex discordant sib pairs from
extended families, whereas X-APL calculated transmis-
sions from parents to affected children only in nuclear
families. Moreover, unaffected male and female siblings
were used in X-APL sex-specific tests to estimate param-
eters, but, again, only same-sex unaffected siblings were
considered in the Kang et al.18 analysis. Nevertheless, the
associated SNPs show some LD ( between2r p 0.23
RS1799836 and RS3027452 in affected females),18 and
both show effects limited to the female subset. Therefore,
it may indicate that there is a yet-untested female risk
variant in LD with the two SNPs.
In conclusion, we have developed X-APL as a powerful,
robust, and versatile tool for family-based associationanal-
ysis on the X chromosome. We demonstrated validity
where other tests failed and showed that X-APL is more
powerful than alternative tests, particularly when parental
genotypes are unavailable, as for individuals with late-
onset diseases. X-APL provides single-marker and global
haplotype tests, as well as separate tests for males and
females, allowing for evaluation of a variety of hypotheses.
As presented here, X-APL uses nuclear families and allows
for missing parental genotypes. XPDT and XMCPDT have
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Table 8. XS-TDT, XPDT, and X-APL





Overall 774 .634 .676 .063
Male 530 .595 .673 .519
Female 329 .175 .349 .036
a Number of families.
b Asymptotic P values for XS-TDT were used.
the advantage of performing analyses for extended pedi-
grees. Similar approaches can be used to modify the APL
and X-APL for extended pedigrees, and the bootstrap pro-
cedure to estimate the variance lends itself easily to this
modification. We have implemented X-APL in a freely
available software package. The X-APL software package
is written in C and is available for use on several com-
puter platforms. It can be publicly accessed at the Duke
Center for Human Genetics Web site.
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Web Resources
The URLs for data presented herein are as follows:
Duke Center for Human Genetics, http://www.chg.duke.edu/
research/software.html (for X-APL software package)
MC-PDT, http://www.stat.ohio-state.edu/˜statgen/SOFTWARE/
MC-PDT/ (for XPDT and XMCPDT)
Michael Knapp’s Web site, http://www.uni-bonn.de/˜umt70e/
soft.htm (for XS-TDT and XRC-TDT)
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for PD, autism, MAOA, and MAOB)
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